Body Composition Analysis in Patients Undergoing Chemoembolization
Hepatocellular carcinoma represents 80-90% of primary hepatic malignant tumors. 80% of patients with hepatocellular carcinoma are associated with cirrhosis.
Chemoembolization is a process in which a chemotherapeutic agent is deposited directly into the hepatic tumor where the principal artery is embolized.
Bioelectrical impedance bases its evaluation in a model where the body is conformed by two different compartments: fat mass and fat free mass.
Bioelectrical impedance is complemented by vectorial analysis, which is independent to the state of hydration and is helpful to monitor any changes in corporal composition. It can be used as a control for the interpretation of the bioelectrical impedance.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||Body Composition Analysis by Bioelectrical Impedance Vector Analysis in Patients With Hepatocellular Carcinoma Undergoing Chemoembolization.|
- Changes in body composition [ Time Frame: 1 hour before treatment, 2 weeks after treatment, and 1 month after treatment ] [ Designated as safety issue: No ]To evaluate any changes in corporal composition in patients undergoing chemoembolization.
|Study Start Date:||April 2012|
|Estimated Study Completion Date:||July 2015|
|Estimated Primary Completion Date:||September 2014 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01777698
|Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán"|
|Mexico city, Mexico, 14000|
|Study Chair:||Aldo Torre, M.D, M.Sc.||Instituto Nacional de Nutrición y Ciencias Médicas "Salvador Zubirán"|